TWC 2022 | 6th Theranostics World Congress

Dear colleagues and friends

At the closing session of the 5th Theranostics World Congress (TWC) 2019 in Jeju, South Korea, we announced that the 6th TWC would be held in Santiago, Chile, in March 2021, symbolized by the traditional handover of the TWC trophy.

Pandemic changed our plans and unfortunately, we had to postpone the TWC-2021. Then came the vaccines, giving a fresh breath back to life and enabling us to connect in-person again. We remain deeply convinced that this meeting should be held face-to-face, facilitating the exchange of ideas, networking, and sparking discussions in the same familiar environment as before. Therefore, it is my great pleasure and honor to welcome you to Wiesbaden for the 6th TWC – but also offer the opportunity to participate virtually.

Wiesbaden is one of the few towns not heavily damaged during the world war and has a lot to offer in history, arts, food including beautiful architecture (e.g., the famous Kurhaus and Theater) as well as Michelin-rated restaurants. The brand-new Rhein-Main Congress Center (RMCC) – located just 20 minutes from Frankfurt airport – will host us during this long-awaited gathering. After breathtaking science, you have the opportunity to relax during a very special evening on June 24th at Kloster (Abbey) Eberbach which is a former Cistercian monastery in Eltville in the Rheingau (the movie version of “The Name of the Rose” brought it to world’s attention).

Please allow us to say, after more than 10 years – the first TWC took place in Bad Berka in 2011 – we are still at the beginnings of the extremely exciting field of Theranostics and Radiomolecular Precision Oncology. But, since the last TWC in 2019, we have witnessed an outstanding growth of Theranostics with an exponential increase in publications, clinical indications, introduction of promising novel radioisotopes and – most importantly – new treatment concepts empowered by patient advocates. Here are just a few recent milestones that we would like to share during the congress:

1. The FDA approval of several 68Ga-PSMA ligands and of 18F DCFPyl for PET/CT imaging
2. Positive results of the Vision trial with 177Lu-PSMA-617 in advanced prostate cancer and approval of PSMA radioligand therapy by FDA in March 2022
3. The emergence of fibroblast activation protein (FAP) as a significant target in the tumor microenvironment (TME) and of numerous FAP-binding radiopharmaceuticals
4. New developments on the radioisotope front such as 161Tb, 152Tb, 212Pb, Cu-64, etc.
5. Development of novel, specific radiopharmaceuticals for targets such as CXCR4, PARP, HER2, integrins, CAIX and many others.
6. New, promising concepts to improve the pharmacokinetic profile of radiopharmaceuticals, including albumin-binding molecules, pre-targeting, bispecific ligands, and others.
7. Increasing number of countries able to offer theranostic treatment to their patients.

2022 is the celebration of 25 years of Peptide Receptor Radionuclide Therapy (PRRT) in Germany which started in Frankfurt/Main in 1997.

There is certainly a lot to learn, discuss and celebrate! Therefore, it’s our great pleasure to invite you to the 6th Theranostic World Congress from June 24 – 26, 2022, in Wiesbaden; the 7th TWC will follow in March 2024, in Santiago, Chile.

Yours sincerely,
Richard P. Baum, Frank Rösch, Vasko Kramer and Horacio Amaral

Advances in Radiochemistry & Radioisotope Production

• Novel isotope production strategies
• New radiolabeling approaches
• Isotope supply
• Advances in chelator chemistry

Clinical Applications

• Theranostics for PCa & NET
• FAP inhibitors
• Novel indications (Adeno-CAs, Sarcomas)

Highlights in Preclinical R&D

• New targets and interesting vectors
• Strategies for PK improvement (e.g., albumin binders)
• Pre-targeting approaches
• Multi-modal theranostics

Nuclear Medicine meets Genetics

• Genetic reasons for (non)responding

Other/Various